I believe this to be the crucial company-maker or company breaker from p.1, (my caps):
"The completion of the non-renounceable rights issue, together with the streamlined operations and the completion of a commercial deal allows Regeneus to be SUFFICIENTLY FUNDED to COMMERCIALIZATION in Japan."
RGS will have little money, but a MUCH stronger negotiating position. Hail Mary, anyone?
OV
PS The post I pulled (above) was right after all. Mine, and mine alone, DEEP bad.
Ann: Appendix 4C - Quarterly, page-12
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.579M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6637 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 4968 | 2 |
View Market Depth
| Last trade - 16.12pm 13/09/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable